CAPRICOR THERAPEUTICS, INC.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$105.0M
- Total assets
- $355.9M
- Market cap
- $1.5B
- Operating margin
- -191.1%
- Net margin
- -181.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $22.3M
- Operating expenses
- $64.8M
- Operating income
- -$42.6M
- Net income
- -$40.5M
- EPS (basic)
- $-1.15
- EPS (diluted)
- $-1.15
Balance sheet
- Total assets
- $170.5M
- Current assets
- $163.4M
- Total liabilities
- $25.0M
- Current liabilities
- $21.0M
- Shareholders’ equity
- $145.5M
Cash flow
- Operating cash flow
- -$40.0M
- Investing cash flow
- -$116.2M
- Financing cash flow
- $152.8M
- Net cash flow
- -$3.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-1.15
- Shares outstanding
- 59.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 20, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $105.0M in FY2025.
- Revenue grew 7078% from FY2020 to FY2024.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CAPRICOR THERAPEUTICS, INC..
Write a review
News about CAPRICOR THERAPEUTICS, INC.
News & sentiment via Polygon.io
